U.S. Markets closed

Ra Medical Systems, Inc. (RMED)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.8100-0.0600 (-1.55%)
At close: 4:00PM EDT
Sign in to post a message.
  • J
    When is this thing going to hold $7?
  • i
    Anyone think RMED will go back to $42.00 per share again?
  • K
    Ra Medical announces extension of DABRA catheter shelf life
    Jan. 27, 2021 3:52 PM ETRa Medical Systems, Inc. (RMED)By: Vandana Singh, SA News Editor
    Ra Medical Systems (RMED -11.9%) reports progress with extending the shelf life of its DABRA catheter of six months or longer, featuring a braided overjacket to improve deliverability. It also said that it has completed all 116 items identified in a quality improvement plan that stemmed from an internal audit in late 2019.
    Though the Company is still implementing multiple remediations to address two primary issues related to the catheter’s limited shelf life as being the introduction of unwanted elements into its core water and the degradation of its inner coating. Engineering work for this catheter is expected to complete by mid-2021 and subsequently submit to the FDA for clearance.
    Dabra excimer laser system is currently in pivotal clinical trial to evaluate the safety and effectiveness as an atherectomy device for the treatment of peripheral arterial disease. Primary efficacy endpoint is the mean reduction in percent diameter stenosis in primary lesion following treatment with Dabra, before any adjunctive treatment.
    Dabra received FDA nod in May 2017 for use in ablating a channel in occlusive peripheral vascular disease.
    The company settled investigations into whether the company made false marketing claims when seeking FDA clearance for Dabra catheter for cardiovascular and skin conditions, earlier in month.
  • C
    Long term pt 30... But have to wait...
  • F
    Big potential there, it was at 500$ remember
  • K
    Ra Medical resolves DOJ false claims investigations
    Jan. 04, 2021 4:03 PM ETRa Medical Systems, Inc. (RMED)By: Vandana Singh, SA News Editor1 Comment
    Ra Medical Systems closed (RMED -4.8%) after settling federal and state investigations into whether the company made false marketing claims when seeking FDA clearance for its laser ablation treatment for cardiovascular and skin conditions.
    The investigation by the U.S. Department of Justice was first disclosed in October 2019, when an audit committee found that the company’s Dabra catheter—a disposable, minimally invasive excimer system designed to break down artery-blocking plaque deposits—”frequently failed to calibrate and occasionally overheated,” risking injury to patients and physicians. The audit also found Ra Medical failed to immediately report the issues to the FDA and began quiet product recalls.
    The settlement with the DOJ, in which Ra Medical does not admit any liability or wrongdoing, as well as includes tentative agreements with participating states that could resolve separate investigations by state attorneys general, the company said.
    Ra Medical will pay an initial $2.5M, plus more depending on future revenues. If sales exceed $10M annually in any of the next four years, the company will be required to pay $500k for 2021, $750k for 2022, $1M for 2023 and $1.25M for 2024.
    Additionally, if the company is bought before the end of 2024, it will be required to pay another $5M, plus 4% of the deal’s value if the transaction tops $100M.
  • i
    happy to see no reverse split talks taking place meaning the management is confident in the stability of the company to meet listing requirement as is.
    cash position is looking good for at least 18 more months with current RD expenses and that is without any revenue. with revenue at this pace, we are looking at 30mnts liquidity.
    Not bad at all...
  • C
    This is a real f up company... Other shares has been up and green many days... This piece of sheet is always 6.66, 6.76, 6.96,... Just sell and go peeps...don't come back at all...
  • J
    .70 to $1 range — Keep on adding shares while it’s still cheap to double, triple, or more on your investment.

    Happy investing!
  • m
    So is this price increase a good thing, I am honestly a little confused???? Help please
  • I
    understand that the shorts aren't going to last to long on this one with it only being 1+ about a week ago this stock has the chance to really change and seeing as advancements in finding the cover cure are high this stock is more intriguing as its a California company its plenty of capital
  • L
    any experts here is this stock a buy at current levels ?
  • S
    Sand Dollar
    Get out RA not going to survive burning Cas to much competition
  • M
    Did anyone else catch this? Clinicaltrials.gov is showing an update was made to the Atherectomy Study today (5/27). Additionally, SEC filings show several insiders bought small chunks of shares today. Hopefully both items are a sign that the stock price will soon increase.


    A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages - Full Text View.
    A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages - Full Text View.
  • V
    RMED moving nicely to reach new highs. I'm so glad I bought my shares at lower prices, but I've added some more.
  • V
    Things are looking up here. Insiders (executives) are buying thousands of shares -- shows confidence. I think RMED stock could reach $25 ~ $30. Just give it time.
  • O
    loaded 123k today. Too easy at this level. Hedge funds loaded the boat recently. Insiders own over 40% of shares FOR A REASON. She will break out from these levels. See you at the top.🍾💸
  • D
    I'm in. Who else in onboard here?
  • J
    Wow this company burns through cash. They just did this and it dropped the stock from the 1.20's down to .50's and now they are doing it again. This is one of those stocks that I really regret buying.
  • D
    Say goodbye to the .40s tomorrow! Get ready for the .50s!!